» Articles » PMID: 16978753

Effects of Topiramate on Methamphetamine-induced Changes in Attentional and Perceptual-motor Skills of Cognition in Recently Abstinent Methamphetamine-dependent Individuals

Overview
Specialty Psychiatry
Date 2006 Sep 19
PMID 16978753
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Methamphetamine-dependent individuals often cite the need to maintain enhanced cognitive performance and attention as a reason for continuing or relapsing to drug-taking. Further, methamphetamine addicts might not comply with taking a potentially therapeutic medication if it had a profound effect on these cognitive processes. Topiramate, a sulfamate-substituted fructopyranose derivative, has been suggested as a putative therapeutic medication for treating methamphetamine dependence. Examination of topiramate's effects on cognitive performance and attention is a clinically and scientifically important component of understanding its potential therapeutic profile. In 10 male and female individuals who met DSM-IV criteria for methamphetamine dependence, we examined the effects of low (50 mg b.i.d.)- and high (100 mg b.i.d.)-dose topiramate - in both the presence and absence of low (15 mg)- and high (30 mg)-dose intravenous methamphetamine--on cognitive performance, attention, and concentration on the rapid visual information processing task and the digit symbol substitution test. Intravenous methamphetamine enhanced cognitive performance, attention, and concentration among recently withdrawn methamphetamine addicts--an effect that hitherto had not been well characterized. Topiramate's cognitive effects were mixed and rather paradoxical, with a tendency to improve attention and concentration both alone and in the presence of methamphetamine while worsening psychomotor retardation. No deleterious interaction occurred between topiramate and methamphetamine on any of these cognitive processes. While clinical studies with topiramate should prepare participants for possible psychomotor retardation, the cognitive effects profile observed would not likely present an important obstacle to compliance in motivated patients. Topiramate's complicated cognitive effects among methamphetamine addicts need more comprehensive examination.

Citing Articles

Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.

Yates J Subst Abuse Rehabil. 2024; 15:125-161.

PMID: 39228432 PMC: 11370775. DOI: 10.2147/SAR.S431273.


Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials.

Acheson L, Williams B, Farrell M, McKetin R, Ezard N, Siefried K Drug Alcohol Rev. 2022; 42(1):7-19.

PMID: 35862266 PMC: 10083934. DOI: 10.1111/dar.13511.


Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial.

Thompson Jr R, Oliveto A, Thostenson J, Wilson M, McGaugh J, Mancino M J Psychopharmacol. 2021; 35(11):1420-1430.

PMID: 34697965 PMC: 10110391. DOI: 10.1177/02698811211050563.


β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly CB2 and Non-CB2 Receptor Mechanisms.

He X, Galaj E, Bi G, He Y, Hempel B, Wang Y Front Pharmacol. 2021; 12:722476.

PMID: 34566647 PMC: 8458938. DOI: 10.3389/fphar.2021.722476.


Environmental Enrichment Prevents Methamphetamine-Induced Spatial Memory Deficits and Obsessive-Compulsive Behavior in Rats.

Hajheidari S, Miladi-Gorji H, Bigdeli I Iran J Psychiatry. 2017; 12(1):8-14.

PMID: 28496496 PMC: 5425356.


References
1.
Johnson B, Oldman D, Goodall E, Chen Y, Cowen P . Effects of GR 68755 on d-amphetamine-induced changes in mood, cognitive performance, appetite, food preference, and caloric and macronutrient intake in humans. Behav Pharmacol. 1996; 7(3):216-27. View

2.
Johnson B, Ait-Daoud N, Bowden C, DiClemente C, Roache J, Lawson K . Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003; 361(9370):1677-85. DOI: 10.1016/S0140-6736(03)13370-3. View

3.
Deutsch S, Schwartz B, Rosse R, Mastropaolo J, Marvel C, Drapalski A . Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol. 2003; 26(4):199-206. DOI: 10.1097/00002826-200307000-00010. View

4.
Morioka T, Nishio S, Ikezaki K, Inamura T, Kawamura T, Fukui K . Unilateral striatal damage following status epilepticus of ipsilateral frontal lobe origin. Seizure. 2002; 11(4):261-5. DOI: 10.1053/seiz.2001.0604. View

5.
Cole B, Robbins T . Forebrain norepinephrine: role in controlled information processing in the rat. Neuropsychopharmacology. 1992; 7(2):129-42. View